Completed
MARS-EDMachine Learning for Risk Stratification in the Emergency Department: a Pilot Clinical Trial
What is being tested
RISK-INDEX
Other
Who is being recruted
Emergencies+5
+ Neurologic Manifestations
+ Pain
Over 18 Years
+5 Eligibility Criteria
How is the trial designed
Diagnostic Study
Interventional
Study Start: September 2022
Summary
Principal SponsorMaastricht University Medical Center
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: September 12, 2022
Actual date on which the first participant was enrolled.See our protocol paper, PMID 38263188
Official TitleMachine Learning for Risk Stratification in the Emergency Department: a Pilot Clinical Trial
Principal SponsorMaastricht University Medical Center
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
1300 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
EmergenciesNeurologic ManifestationsPainPathologic ProcessesSigns and SymptomsPathological Conditions, Signs and SymptomsDisease AttributesAcute Pain
Criteria
3 inclusion criteria required to participate
Adult, defined as ≥ 18 years of age
Assessed and treated by an internal medicine specialist (gastroenterologists included) in the ED
Willing to give written consent, either directly or after deferred consent procedure (see section 11.2).
2 exclusion criteria prevent from participating
4 different laboratory results available (hematology or clinical chemistry) within the first two hours of the ED visit (calculation ML prediction score otherwise not possible)
Unwilling to provide written consent, either directly or after deferred consent procedure (see section 11.2).
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalRoutine clinical care. Physicians will actively be asked to self-report their clinical impression of each included patient and policy will be monitored. In the intervention group, physicians will be presented with the RISKINDEX. Subsequently, self-report will again be initiated to evaluate the physicians' response to the ML score and possible policy changes due to the intervention.
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
Maastricht University Medical Centre
Maastricht, NetherlandsOpen Maastricht University Medical Centre in Google MapsCompletedOne Study Center